Michael Coyle
Director/Board Member chez HAEMONETICS CORPORATION
Fortune : 895 663 $ au 31/03/2024
Profil
M. Michael J. Coyle est président, directeur général et directeur d'iRhythm Technologies, Inc. et directeur indépendant d'Haemonetics Corp, président de HeartWare International, Inc, vice-président exécutif et président du groupe cardiaque et vasculaire de Medtronic, Inc, directeur général de Medtronic 3F Therapeutics, Inc et directeur général de Medtronic ATS Medical, Inc. Il est membre du conseil d'administration d'iRhythm Technologies, Inc. et d'Haemonetics Corp. Auparavant, M. Coyle a été employé en tant que président du groupe cardiaque et vasculaire de Medtronic Plc, directeur indépendant de Volcano Corp, président et directeur de l'exploitation de Daig Corp, président de la division de gestion du rythme cardiaque de St. Jude Medical LLC et directeur d'Eli Lilly & Co. Il a également siégé au conseil d'administration de VNUS Medical Technologies, Inc. Il a obtenu son diplôme de premier cycle à l'université Case Western Reserve et un MBA à la Wharton School de l'université de Pennsylvanie.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
HAEMONETICS CORPORATION
0,02% | 04/08/2023 | 10 494 ( 0,02% ) | 895 663 $ | 31/03/2024 |
Postes actifs de Michael Coyle
Sociétés | Poste | Début |
---|---|---|
HAEMONETICS CORPORATION | Director/Board Member | 16/04/2020 |
Medtronic ATS Medical, Inc.
Medtronic ATS Medical, Inc. Medical SpecialtiesHealth Technology Medtronic ATS Medical, Inc. develops, manufactures and markets medical devices for the treatment of structural heart disease. The company was founded on November 09, 2000 and is headquartered in Minneapolis, MN. | Chief Executive Officer | - |
Medtronic 3F Therapeutics, Inc.
Medtronic 3F Therapeutics, Inc. Medical SpecialtiesHealth Technology Medtronic 3F Therapeutics, Inc. develops, manufactures and markets cardiovascular devices. The company is headquartered in Minneapolis, MN. | Chief Executive Officer | - |
Baropace, Inc.
Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Director/Board Member | - |
Anciens postes connus de Michael Coyle
Sociétés | Poste | Fin |
---|---|---|
IRHYTHM TECHNOLOGIES, INC. | Chief Executive Officer | 01/06/2021 |
Medtronic, Inc.
Medtronic, Inc. Medical SpecialtiesHealth Technology Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN. | Corporate Officer/Principal | 01/01/2021 |
MEDTRONIC PLC | Corporate Officer/Principal | 31/12/2020 |
VNUS Medical Technologies, Inc.
VNUS Medical Technologies, Inc. Medical SpecialtiesHealth Technology VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA. | Director/Board Member | 17/06/2009 |
ST JUDE MEDICAL INC | Corporate Officer/Principal | 31/12/2007 |
Formation de Michael Coyle
Case Western Reserve University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 4 |
---|---|
ELI LILLY AND COMPANY | Health Technology |
HAEMONETICS CORPORATION | Health Technology |
IRHYTHM TECHNOLOGIES, INC. | Health Technology |
MEDTRONIC PLC | Health Technology |
Entreprise privées | 9 |
---|---|
Daig Corp.
Daig Corp. Medical SpecialtiesHealth Technology Part of Abbott Laboratories, Daig Corp. is a private company that manufactures specialty catheters. The company is based in Hopkins, MN. Daig was acquired by St. Jude Medical LLC, part of Abbott Laboratories from January 05, 2017 on May 31, 1996 for $439.60 million. | Health Technology |
Medtronic, Inc.
Medtronic, Inc. Medical SpecialtiesHealth Technology Medtronic, Inc. operates as a medical technology company. It offers implantable cardiac pacemakers, eternal defibrillators, inferior turbinate surgery products, and continuous glucose monitoring device. The company was founded by Earl E. Bakken and Palmer J. Hermundslie on April 29, 1949 and is headquartered in Minneapolis, MN. | Health Technology |
St. Jude Medical LLC
St. Jude Medical LLC Medical SpecialtiesHealth Technology St. Jude Medical LLC develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiovascular and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. The company was founded by Manuel A. Villafana in 1976 and is headquartered in St. Paul, MN. | Health Technology |
Medtronic ATS Medical, Inc.
Medtronic ATS Medical, Inc. Medical SpecialtiesHealth Technology Medtronic ATS Medical, Inc. develops, manufactures and markets medical devices for the treatment of structural heart disease. The company was founded on November 09, 2000 and is headquartered in Minneapolis, MN. | Health Technology |
VNUS Medical Technologies, Inc.
VNUS Medical Technologies, Inc. Medical SpecialtiesHealth Technology VNUS Medical Technologies, Inc. provides medical devices and procedures for the minimally invasive treatment of venous reflux disease, an underlying cause of varicose veins. Venous reflux disease results in symptoms such as leg pain, swelling, fatigue, skin ulcers, and painful varicose veins. The company was founded on January 31, 1995 and is headquartered in San Jose, CA. | Health Technology |
Philips Image Guided Therapy Corp.
Philips Image Guided Therapy Corp. Medical SpecialtiesHealth Technology Volcano Corp. designs, develops and manufactures a broad suite of intravascular ultrasound products. The company was founded by Olav B. Bergheim and Samuel Ward Casscells and is headquartered in San Diego, CA. | Health Technology |
HeartWare International LLC
HeartWare International LLC Medical SpecialtiesHealth Technology HeartWare International LLC is a medical device company, which engaged in the development and manufacturing of miniaturized implantable heart pumps or ventricular assist devices to treat patients suffering from advanced heart failure. The company was founded on July 29, 2008 and is headquartered in Framingham, MA. | Health Technology |
Medtronic 3F Therapeutics, Inc.
Medtronic 3F Therapeutics, Inc. Medical SpecialtiesHealth Technology Medtronic 3F Therapeutics, Inc. develops, manufactures and markets cardiovascular devices. The company is headquartered in Minneapolis, MN. | Health Technology |
Baropace, Inc.
Baropace, Inc. Electronic Equipment/InstrumentsElectronic Technology Baropace, Inc. is a privately held medical device company located in Ashland, OR. Baropace is focused on the development of pressurepace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (hfpef). The company has proprietary biotechnologies including a pacemaker control algorithm (pressurepace™) and new sensor technologies working through patient mobile and wearable platforms. Baropace expects to launch a first-in-human clinical trial (relievehtn-i) in the fourth quarter of 2022. Pressurepace™ is limited by federal law to investigational use only and is not approved for sale in any geography. The company was founded in 2019 by Eli Gang and Michael Burnam, who has been the CEO since 2018. | Electronic Technology |